Chester County News and Community Website
NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported a 68% tumor response rate and median progression-free survival of 16 months at the higher dose of its experimental lung …
ArriVent Lung Cancer Drug Shows 68% Response Rate in Trial Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) has dosed the first patient in a U.S. Phase 1 clinical trial of ARR-002, an experimental antibody-drug conjugate targeting ovarian and …
ArriVent Advances Cancer Drug Pipeline With First U.S. Trial Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) said its experimental lung cancer drug firmonertinib failed to significantly improve progression-free survival compared with chemotherapy in a pivotal Phase 3 …
ArriVent’s Lung Cancer Drug Fails Key Phase 3 Trial Endpoint Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (NASDAQ: AVBP) is approaching a pivotal Phase 3 readout for its lead lung cancer drug while advancing two antibody-drug conjugates into later stages …
ArriVent Nears Pivotal Lung Cancer Data With $373 Million Cash Read More NEWTOWN SQUARE, PA — ArriVent BioPharma (Nasdaq: AVBP) reported first-quarter results as the company advanced late-stage testing of its lung cancer therapy firmonertinib and moved two antibody-drug conjugate programs closer …
ArriVent BioPharma Advances Lung Cancer Program, ADC Pipeline Read More NEWTOWN SQUARE, PA — ArriVent BioPharma (Nasdaq: AVBP) received U.S. Food and Drug Administration clearance to begin human testing of an experimental antibody-drug conjugate designed to improve targeting of ovarian …
ArriVent Pushes Dual-Target Ovarian Cancer Drug Into Trials Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) will present preclinical data on two cancer drug candidates at the American Association for Cancer Research Annual Meeting 2026 in San …
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 Read More NEWTOWN SQUARE, PA — ArriVent BioPharma Inc. (Nasdaq: AVBP) reported financial results for the year ended December 31, 2025, and said it expects pivotal Phase 3 data for its lung …
ArriVent Reports 2025 Results, Plans Phase 3 Data for Firmonertinib Read More NEWTOWN SQUARE, PA — ArriVent BioPharma has dosed the first patient in a global Phase 3 study that could reshape first-line treatment for a small but hard-to-treat group of lung …
Firmonertinib Trial Aims to Crack a Long-Standing Lung Cancer Treatment Gap Read More NEWTOWN SQUARE, PA — ArriVent BioPharma, Inc. (Nasdaq: AVBP) reported third-quarter financial results and outlined major clinical milestones that position the company for a pivotal two-year stretch focused on advancing …
ArriVent Maps Ambitious 2026 Oncology Push as Firmonertinib Program Gains Steam Read More